RRML - FasL is expressed in human breast cancer endothelia. Who benefits?

Main page
News
RJLabM Credits
Archive
- Current issue
- Ahead of print
- List of published issues
- 2024
  - Nr.1/2024
- 2023
  - Nr.4/2023
  - Nr.3/2023
  - Nr.2/2023
  - Nr.1/2023
  - Supplement 1/2023
- 2022
  - Nr.4/2022
  - Nr.3/2022
  - Nr.2/2022
  - Nr.1/2022
  - Supplement 1/2022
- 2021
  - Nr.4/2021
  - Nr.3/2021
  - Nr.2/2021
  - Nr.1/2021
- 2020
  - Nr.4/2020
  - Nr.3/2020
  - Nr.2/2020
  - Nr.1/2020
  - Supplement 1/2020
- 2019
  - Nr.4/2019
  - Nr.3/2019
  - Nr.2/2019
  - Nr.1/2019
  - Supplement 1/2019
- 2018
  - Nr.4/2018
  - Nr.3/2018
  - Nr.2/2018
  - Nr.1/2018
  - Supplement 1/2018
  - Supplement 2/2018
  - Supplement 3/2018
- 2017
  - Nr.4/2017
  - Nr.3/2017
  - Nr.2/2017
  - Nr.1/2017
  - Supplement 1/2017
- 2016
  - Nr.4/2016
  - Nr.3/2016
  - Nr.2/2016
  - Nr.1/2016
  - Supplement 1/2016
- 2015
  - Nr.4/2015
  - Nr.3/2015
  - Nr.2/2015
  - Nr.1/2015
  - Supplement 1/2015
- 2014
  - Nr.4/2014
  - Nr.3/2014
  - Nr.2/2014
  - Nr.1/2014
  - Supplement 1/2014
- 2013
  - Nr.4/2013
  - Nr.3/2013
  - Nr.2/2013
  - Nr.1/2013
  - Supplement 1/2013
- 2012
  - Nr.4/2012
  - Nr.3/2012
  - Nr.2/2012
  - Nr.1/2012
  - Supplement 1/2012
- 2011
  - Nr.4/2011
  - Nr.3/2011
  - Nr.2/2011
  - Nr.1/2011
  - Supplement 1/2011
- 2010
  - Nr.4/2010
  - Nr.3/2010
  - Nr.2/2010
  - Nr.1/2010
  - Supplement 1/2010
- 2009
  - Nr.4/2009
  - Nr.3/2009
  - Nr.2/2009
  - Nr.1/2009
  - Supplement 1/2009
- 2008
  - Nr.4/2008
  - Nr.3/2008
  - Nr.2/2008
  - Nr.1/2008
  - Supplement 1/2008
- 2007
  - Nr.4/2007
  - Nr.3/2007
  - Nr.2/2007
  - Nr.1/2007
- 2006
  - Nr.4/2006
  - Nr.3/2006
  - Nr.2/2006
  - Nr.1/2006
- 2005
  - Nr.1/2005
Instructions for authors
Online applications
- Send an article
- Online payments
Editorial
About us
Links

ISSN online: 2284-5623

ISSN-L: 1841-6624

Rejection rate (2020): 75%

Journal Metrics

Impact Factor 0.5
Five Year Impact Factor 0.5
JCI 0.12

Top 10 downloaded articles - April 2024 -

A comprehensive review of Prof...	24
Recomandarea comună EFLM-COLA...	13
Monocyte to high-density lipop...	9
Anti-thyroid peroxidase (TPO) ...	9
Understanding the key differen...	7
Understanding the pathogenesis...	7
Function of the S1P pathway in...	6
Predictive value of expression...	5
The importance of tumor marker...	4
Romanian Review of Laboratory ...	4

Concept, Design & Programming
Dr. Adrian Man

Nr. 20(1)/2012

FasL is expressed in human breast cancer endothelia. Who benefits?

Corina M. Cianga, Irina D. Florea, Petru Cianga

Abstract:

Background: Fas ligand (FasL) expression is one of the mechanisms responsible for the “immune privi-lege” of tissues such as testis and eye. Many solid tumors express FasL as an immune escape strategy, aiming to induce apoptosis in Fas-expressing leukocytes, and thus to prevent the accumulation of effector cells. Materials and Methods: We investigated by immunohistochemistry the FasL expression in human breast carcinomas vasculature (blood vessels versus lymphatics), endothelial activation status and markers associated with tumor aggressiveness. Results: We bring evidence of a heterogeneous FasL expression in the human breast carcinomas associated blood vessels, but not lymphatics. The endothelial FasL expression was significantly correlated with the tumor FasL expression, tumor size, the presence of rich vascular networks, and axillary lymph nodes metastases; however, it was not correlated with low tumor invading leukocytes density. Conclusion: Breast carcinomas are among tumors in which the tumor-host interaction is correlated with the clinical outcome, hence understanding the significance of endothelial FasL expression is of outmost importance.

Keywords: FasL,breast carcinoma,endothelium,immune privilege,tolerance

Download full text PDF
(651 KB)

Cianga CM, Florea ID, Cianga P. FasL is expressed in human breast cancer endothelia. Who benefits?. Rev Romana Med Lab. 2012;20(1):45-56